The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Interleukin 6/Gp130–Dependent Pathways Are Protective During Chronic Liver Diseases
Abstract
The contribution of the acute phase inducer interleukin 6 (IL–6) in the pathogenesis of liver diseases is yet unclear. Our analysis showed enhanced expression of IL–6 in livers derived from patients with acute and chronic liver diseases. Additionally, IL–6 plasma levels were significantly increased in patients with chronic liver diseases and showed an inverse correlation with biochemical markers of liver function and a positive correlation with inflammatory markers, signs of portal hypertension, and the degree of liver fibrosis. To prove the relevance of these clinical findings, we applied the tetrachlorcarbonide (CCl 4) model to conditional knockout animals (Cre/loxP system) for gp130, the common signal transducer of IL–6 family cytokines. Cre recombinases were expressed through a hepatocyte (AlfpCre) and a ubiquitous (MxCre) control element. Gp130 deleted mice had a totally abolished STAT3 activation and acute phase response induction, but gp130 deletion had no effect on the degree of acute liver injury and subsequent hepatocyte proliferation. In contrast, during chronic liver injury induced by biweekly application of CCl 4, deletion of the gp130 receptor in nonparenchymal liver cells and not hepatocytes resulted in fibrosis progression. In conclusion, our experiments indicate an involvement of IL–6 in the pathogenesis of liver diseases and suggest a protective role of IL–6/gp130–dependent pathways in nonparenchymal liver cells during fibrosis progression in chronic liver diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
HEINRICH, P. C., BEHRMANN, I., MÜLLER-NEWEN, G., SCHAPER, F., & GRAEVE, L. (1998) · Biochemical Journal · doi:10.1042/bj3340297 · Cited by 2,130
Impaired immune and acute-phase responses in interleukin-6-deficient mice
Kopf, M., Baumann, H., Freer, G., Freudenberg, M., Lamers, M., Kishimoto, T., Zinkernagel, R., Bluethmann, H., & Köhler, G. (1994) · Nature · doi:10.1038/368339a0 · Cited by 1,768
Liver Failure and Defective Hepatocyte Regeneration in Interleukin-6-Deficient Mice
Cressman, D. E., Greenbaum, L. E., DeAngelis, R. A., Ciliberto, G., Furth, E. E., Poli, V., & Taub, R. (1996) · Science · doi:10.1126/science.274.5291.1379 · Cited by 1,538
Alonzi, T., Maritano, D., Gorgoni, B., Rizzuto, G., Libert, C., & Poli, V. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.5.1621-1632.2001 · Cited by 329
Increased toxin-induced liver injury and fibrosis in interleukin-6-deficient mice
Kovalovich, K., DeAngelis, R. A., Li, W., Furth, E. E., Ciliberto, G., & Taub, R. (2000) · Hepatology · doi:10.1002/hep.510310123 · Cited by 298
Galun, E., Zeira, E., Pappo, O., Peters, M., & Rose-John, S. (2000) · The FASEB Journal · doi:10.1096/fj.99-0913com · Cited by 124
Hillebrandt, S., Goos, C., Matern, S., & Lammert, F. (2002) · Gastroenterology · doi:10.1053/gast.2002.37069 · Cited by 104
Concanavalin A-induced liver injury triggers hepatocyte proliferation.
Trautwein, C., Rakemann, T., Malek, N. P., Plümpe, J., Tiegs, G., & Manns, M. P. (1998) · Journal of Clinical Investigation · doi:10.1172/jci504 · Cited by 87
Self-citation
Cited by
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Michalopoulos, G. K. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21172 · Cited by 1,384
Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver
Lu, L., Li, Y., Kim, S. M., Bossuyt, W., Liu, P., Qiu, Q., Wang, Y., Halder, G., Finegold, M. J., Lee, J.-S., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911427107 · Cited by 721
Radaeva, S., Sun, R., Pan, H.-N., Hong, F., & Gao, B. (2004) · Hepatology · doi:10.1002/hep.20184 · Cited by 597
Plasticity and cross-talk of Interleukin 6-type cytokines
Garbers, C., Hermanns, H. M., Schaper, F., Müller-Newen, G., Grötzinger, J., Rose-John, S., & Scheller, J. (2012) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2012.04.001 · Cited by 400
Metadata
- Authors
- Streetz, K. L., Tacke, F., Leifeld, L., Wüstefeld, T., Graw, A., Klein, C., Kamino, K., Spengler, U., Kreipe, H., Kubicka, S., Müller, W., Manns, M. P., & Trautwein, C.
- Venue
- Hepatology
- Published
- 2003-07
- Volume
- 38
- Issue
- 1
- Pages
- 218-229
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2098193724
- Cited by
- 167
- References
- 8
- FWCI
- 7.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interleukin 6/Gp130–Dependent Pathways Are Protective During Chronic Liver Diseases. https://app.cochat.ai/papers/10.1053/jhep.2003.50268
- The paper
- Streetz, K. L., Tacke, F., Leifeld, L., Wüstefeld, T., Graw, A., Klein, C., Kamino, K., Spengler, U., Kreipe, H., Kubicka, S., Müller, W., Manns, M. P., & Trautwein, C. (2003). Interleukin 6/Gp130–Dependent Pathways Are Protective During Chronic Liver Diseases. Hepatology. https://doi.org/10.1053/jhep.2003.50268
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.